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Background: Multiple reviews have demonstrated that mood disorders are associated 
with abnormal pro- and anti-inflammatory immunological markers and recent studies 
suggest that anti-inflammatory medication may play an important role in the treatment 
of mood disorders.   
 
Aims:  
1. To evaluate current evidence on the efficacy and acceptability of anti-
inflammatory drugs in patients with major depressive disorder (MDD) and bipolar 
disorder.  
2. To determine whether the anti-inflammatory tetracycline antibiotic minocycline, 
added to treatment as usual (TAU) for 3 months in patients with treatment-resistant 
depression leads to an improvement in depressive symptoms and if so, to estimate 
effect sizes to inform the development of a larger, hypothesis-testing study. 
 
Methods: A systematic review and meta-analysis of published trials of anti-
inflammatory agents in mood disorders was conducted. The Cochrane Central Register 
of Controlled Trials, PubMed, EMBASE, PsychINFO and Clinicaltrials.gov were searched 
from inception until April 15, 2017 for completed and on-going clinical trials of anti-
inflammatory agents for MDD and bipolar disorder. Data from randomized controlled 
trials (RCTs) assessing the antidepressant and antimanic effect of adjunctive 
mechanistically diverse anti-inflammatory agents were pooled to determine standard 
mean differences (SMDs) compared with placebo and/or treatment as usual.  
 
To address the second aim a multi-site, 12-week, double blind, placebo-controlled, pilot 
trial was conducted. The trial was of minocycline added to treatment as usual for 
patients suffering from DSM-5 major depressive disorder whose current episode has 
failed to respond to at least 2 antidepressants. The primary outcome measure was mean 








12. Secondary measures were the Clinical Global Impression scale (CGI), Patient Health 
Questionnaire-9 (PHQ-9), the Generalised Anxiety Disorder scale (GAD-7) and EuroQoL 
(EQ-5D).  Side effects checklists were also used. Minocycline was started at 100 mg once 
daily (OD) and increased to 200 mg OD after two weeks.   
 
Results: The meta-analysis found that patients receiving anti-inflammatory agents 
showed lower post-treatment depressive symptom scores compared with those 
receiving placebo with a SMD of -0.71 (6 RCTs, n=214, 95% CI -1.24 to -0.17, p=0.009).  
Anti-inflammatory treatment was found to reduce post-treatment manic symptom 
scores with a SMD of -0.72 (3 RCTs, n=96, 95% CI -1.31 to -0.13, p=0.02). Anti-
inflammatory treatment was found to yield an improvement in depressive symptom 
scores from baseline to outcome with a SMD of -0.52 (5 RCTs, n=194, 95% CI -1.01 to 
0.05) but this was not statistically significant (p=0.07).  
 
In the pilot RCT, a total of 41 participants were randomised, with 21 in the 
minocycline group and 20 in the placebo group. A large decrease in HAMD scores was 
observed in the minocycline group compared to the placebo group (Standardized effect 
size -1.21, p < 0.001). CGI scores in the minocycline group also showed a 
large improvement compared with placebo (OR: 17.6, p < 0.001). PHQ-9 (ES -0.43), 
GAD-7 (ES -0.46) and EQ-5D total (ES -0.48) showed more moderate improvements. 
 
Conclusions: Anti-inflammatory treatments may confer benefit for both depressive and 
manic symptoms however current studies are limited by small sample sizes, short 
durations, differing baseline symptomatology and poorly defined illness durations. The 
findings of the pilot RCT indicate that adjunctive minocycline leads to improvement 
in symptoms of treatment-resistant depression. However, the findings 
require replication in a larger sample. Overall, further high-quality trials are needed 
before making recommendations for the routine clinical use of anti-inflammatory 
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Chapter 1: Introduction 
 
1.1 Prevalence of mood disorders and the burden of treatment resistance 
Mood disorders i.e. major depressive disorder (MDD) and bipolar disorder are a leading 
cause of morbidity and mortality across the globe. Major depressive disorder was 
recently identified as the leading cause of ill health and disability worldwide (WHO, 
2017). These conditions are frequently chronic and debilitating, often with poor 
recovery between episodes (Rush et al., 2006, Malhi et al., 2007, Marotta et al., 2015).  
 
Accurate data on the prevalence of mood disorders does not exist for most countries 
and available evidence suggests that there is wide variability in prevalence estimates 
between countries. A systematic review of 18 prevalence and 5 incidence studies of 
mood disorders found significant variation across 1-year and lifetime prevalence of 
MDD and bipolar I disorder. The corresponding pooled rates for 1-year prevalence were 
4.1 per 100 and 0.72 per 100, respectively. For lifetime prevalence, the corresponding 
pooled rates were 6.7 per 100 and 0.8 per 100, respectively (Waraich et al., 2004).  
 
More recently there has been published data on the prevalence of ICD-10 (International 
Statistical Classification of Diseases and Related Health Problems 10th revision) 
depressive episodes in the WHO (World Health Organisation) World Health Survey 
across 60 countries. Twelve-month prevalence averaged 3.2% in participants without 
comorbid physical disease and 9.3% to 23.0% in participants with chronic physical 
health conditions (Moussavi et al., 2007). The WHO World Mental Health (WMH) Survey 
Initiative summarised 12-month prevalence estimates of DSM-IV (Diagnostic and 
Statistical Manual of Mental Disorders 4th revision) major depressive episodes in 18 
WMH countries ranged from 2.2% (Japan) to 10.4% (Brazil) (Kessler et al., 2010). The 
mid-point across all countries was similar to that in previous surveys (5%), as was the 
weighted average 12-month prevalence for the ten high-income (5.5%) and eight low 








The WMH survey also provided data on the prevalence of bipolar disorder, which 
Merikangas et al., summarised in 2011. They reported that the aggregate lifetime 
prevalence of bipolar-I disorder was 0.6%, bipolar-II was 0.4%, sub-threshold bipolar 
was 1.4%, and Bipolar Spectrum (BPS) was 2.4%. Twelve-month prevalence of bipolar-I 
disorder was 0.4%, bipolar-II was 0.3%, sub-threshold bipolar was 0.8%, and BPS was 
1.5% (Merikangas et al., 2011). 
 
Although both depressive and manic symptoms are amenable to pharmacological 
treatments, a high proportion of patients neither responds nor achieves remission 
(Perlis et al., 2006, Rush et al., 2006, Vergunst et al., 2013). Many patients are also left 
suffering from a significant decline in their social and occupational functioning (Mahli et 
al., 2007). The Sequenced Treatment Alternatives for the Relief of Depression (STAR*D) 
study, a large naturalistic study of over 3500 patients with MDD showed that the 
response and remission rates with stage 1 treatment (i.e. the selective serotonin 
reuptake inhibitor citalopram) were 49% and 37%, respectively. Response rates over 
the subsequent next three treatment steps decreased to 16% and 13%, respectively, 
(Rush et al., 2006). A recent meta-analysis of current pharmacological treatments for 
depressive disorder in primary care showed only a relatively small effect size for 
antidepressant treatments when compared to placebo (Linde et al., 2015). Similarly, 
studies in bipolar disorder, such as the Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD) showed that only 58.4% of 
patients that receive adequate treatment according to current practice guidelines 
subsequently achieve partial or full remission (Perlis et al., 2006). It is therefore evident 
that there remains a significant need for more efficacious and novel treatment 
approaches. 
 
1.2 Inflammation and its associations with mood disorders 
In 1887 Julius Wagner-Jauregg was the first individual to study an association between 
the immune response and mental illness when he induced malaria in patients to 








referred to as “general paralysis of the insane”,  led to cognitive decline, psychotic 
symptoms and paresis, which were later found to be the neuropsychiatric 
manifestations of cerebral syphilis  (Raju, 1998). Since then there have been numerous 
studies linking inflammatory processes to a range of psychiatric illness, including MDD 
and bipolar disorder. Multiple reviews of clinical and pre-clinical data have clearly 
demonstrated that MDD and bipolar disorder are associated with abnormal profiles of 
circulating pro- and anti-inflammatory biomarkers in affected patients (Goldstein et al., 
2009; Howren et al., 2009; O’ Donovan et al., 2013). Individuals with a raised 
inflammatory profile have been shown to have alterations in mood, sleep, energy, 
cognition, and motivation, all of which can form part of the presentation of a mood 
disorder. To understand putative aetiological models linking inflammation to mood 
disorders, it is important to discuss the functioning of the normal human immune and 
inflammatory response systems.   
 
The immune response is divided into the innate and adaptive systems. The innate 
response is activated by pathogen associated molecular patterns (PAMPs), which cause 
the release of chemical factors including histamines, prostaglandins, bradykinin, 
serotonin, and leukotrienes (Abbas et al., 2012). Prostaglandins and thromboxanes are 
produced through the actions of enzymes calcium-dependent phospholipase A2 and 
cyclooxygenase (COX)-1 and 2, on arachidonic acid. These chemical factors produce the 
local inflammatory response causing signs and symptoms such as vasodilation and pain. 
They also attract macrophages to the site of inflammation. The macrophages release 
proteins called cytokines, such as Tumour Necrosis Factor (TNF)-α, Interleukin (IL)-1 
and IL-6, to initiate a systemic inflammatory response and adaptive immune response 
by attracting leukocytes and lymphocytes (Abbas et al., 2012). 
 
The adaptive immune response creates and maintains the immune system's memory. T-
lymphocytes produce a response to terminate cells identified as potentially pathogenic. 








lymphocytes. B-lymphocytes are also attracted and stimulated by the cytokines to 
produce antibodies against the pathogens (Abbas et al., 2012). 
 
The cytokines and chemical factors produced during this inflammatory response can be 
used as biomarkers for investigating the potential association between inflammation 
and mood disorders. The evidence that mood disorders (or some subgroups thereof) 
are inflammatory-related disorders comes from multiple sources. These include a study 
demonstrating that peripheral administration of a pro-inflammatory cytokine 
(interferon-α, IFN- α) induces a depressive syndrome in many patients receiving it as a 
treatment for hepatitis (Van Gool et al., 2003). Treatment with cytokine IFN-α 
corresponds with the development of depressive symptoms in up to 45% of patients 
with no previous history of depression (Capuron & Miller, 2011).  
 
Cytokines and chemokines are key regulators of immune function, with some of these 
mediators having a pro-inflammatory effect (e.g. interleukin-1 (IL-1), IL-12, and IL-18, 
tumour necrosis factor (TNF), interferon gamma (IFN-gamma)), whereas others are 
mainly anti-inflammatory (e.g. IL-1 receptor antagonist, IL-4, IL-6, IL-10, IL-11, and IL-
13) (Raison et al., 2006). Longitudinal studies have demonstrated that high plasma pro-
inflammatory cytokine levels precede, and thus potentially cause depressive symptoms 
(Khandaker et al., 2014; Gimeno et al., 2009).  However, emerging evidence indicates 
that this subdivision may be overly simplistic. For example, IL‐6 may activate a classical 
pathway and a trans‐signaling pathway, which may have predominantly anti‐ and pro-
inflammatory activities respectively (Maes et al., 2014). In a recent systematic review 
and meta-analysis of eighty‐two studies comprising 3212 participants with MDD and 
2798 healthy controls there was a highly heterogeneous balance of peripheral levels  of 
“pro-” vs. “anti-”inflammatory cytokines in individuals with MDD; levels IL‐6, TNF‐
alpha, IL‐10, the soluble IL‐2 receptor, C‐C chemokine ligand 2, IL‐13, IL‐18, IL‐12, the 
IL‐1 receptor antagonist, and the soluble TNF receptor 2 were elevated in patients with 
MDD compared to healthy controls, whereas IFN‐gamma levels were lower in MDD 








Notwithstanding this, the most convincing evidence for a close relationship between 
inflammation and mood is the very frequent comorbidity of depressive symptoms with 
virtually all chronic inflammatory or autoimmune disorders (Capuron & Miller, 2011). 
Large proportions (probably greater than 50%) of patients with rheumatoid arthritis 
and systemic lupus erythematosus (SLE) have depressive or other psychiatric 
symptoms. Inflammatory physical disorders, both central and peripheral, are associated 
with greater rates of depression and in patients with Crohn’s disease and comorbid 
depression, bouts of physical disease activity tend to co-occur with depressive episodes 
(Mardini et al., 2004).   Although less robust, evidence also suggests that inflammation 
when present is associated with a more severe course of illness (Zalli et al., 2015), and 
more prominent in people whom are resistant to monoaminergic drugs (Carvalho et al., 
2013; Grosse et al., 2015).  
 
Bipolar disorder has also been proposed as a multi-systemic inflammation-related 
illness due to the significant inflammatory comorbidity associated with it (Leboyer et 
al., 2012). Several studies have demonstrated an association between bipolar disorder 
and inflammatory conditions including autoimmune disorders such as SLE (Perugi et al., 
2014), chronic infections such as Toxoplasma gondii (Sutterland et al., 2015), 
cardiovascular disease (SayuriYamagata et al., 2017) and metabolic disorders such as 
diabetes, obesity and hypercholesterolemia (Perugi et al., 2014).  Cytokine studies 
comparing patients with bipolar disorder to healthy controls have revealed elevated 
circulating levels of cytokines involved in both the innate (e.g. TNF-α, IL-6, IL-1 receptor 
antagonist (IL-1RA) and C-reactive protein (CRP)) and adaptive immune response (e.g. 
IL-4, IL-6 and IL-10) (Dargel et al., 2015; Goldsmith et al., 2016; Modabbernia et al., 
2013; Munkholm et al., 2013a & b; Stuart & Baune 2014) in patients with bipolar 
disorder. Studies also demonstrate abnormal expression of other inflammatory 
chemokines, including those involved in the migration of neutrophils, monocytes and 
macrophages and several T-cell phenotypes (Bai et al., 2014, 2015; Barbosa et al., 2013; 
Bietzke et al., 2009; Drexhage et al., 2010 & 2011; O’ Brien et al., 2006; Padmos et al., 








levels of neutrophils, monocytes and several T-cell subsets (Barbosa et al., 2015; 
Brambilla et al., 2014; Breunis et al., 2003; do Prado et al., 2013; Drexhage et al., 2011; 
Jakobsson et al., 2015; Kalelioglu et al., 2015; Tsai et al., 2012 & 2014).  
 
Despite these associations, the direction of causality between mood disorder and 
systemic inflammation remains unclear. It is likely that the causality is multi-directional 
and that an abnormal inflammatory response, a mood disorder and inflammatory 
physical health comorbidities are all perpetuating factors for each other. Moreover, 
genetic and environmental risk factors for an abnormal inflammatory response may 
increase the risk of developing both a mood disorder and inflammatory physical health 
conditions. 
 
1.3 Pathophysiological models linking inflammation to mood disorders 
Although several putative aetiological models have been proposed to connect 
inflammation to mood disorders, the most consistent appears to be the cytokine 
hypothesis. As discussed earlier, pro-inflammatory cytokines have repeatedly been 
shown to be elevated in patients with mood disorders. These cytokines have been 
shown to affect central serotonin levels, the hypothalamic–pituitary–adrenal (HPA) axis, 
and microglial activation as well as brain structure (Rosenblat et al., 2014; Miller & 
Raison, 2016). 
 
Reduced serotonin production and increased serotonin depletion are thus far the most 
commonly proposed mechanisms of mood disorder aetiology. In animal studies 
cytokines IL-6 and TNF-α have been shown to increase the breakdown of serotonin 
through facilitating its conversion to 5-hydroxyindoleacetic acid (Wang & Dunn, 1998; 
Zhang et al., 2001). Similarly, cytokines IL-2 and IFN have been shown to directly 
increase the activity of indolamine 2,3-dioxygenase (IDO), an enzyme that increases the 
conversion of tryptophan to kynurenine and consequently decreases the production of 








quinolonic acid have also been shown to independently induce depressive and anxiety 
symptoms (Maes et al., 2011).  
 
The physiological stress response induced by inflammation is known to activate the 
HPA axis and several studies have also shown that cytokines are involved in increasing 
levels of corticotrophin releasing hormone (CRH), adrenocorticotropic hormone 
(ACTH) and cortisol (Brydon et al., 2009; Pace & Miller, 2009). Cytokines have also been 
shown to increase cortisol levels by blocking the negative feedback loop of the HPA axis 
by decreasing the expression, translocation and downstream effects of glucocorticoid 
receptors (Pace & Miller, 2009). Elevated cortisol levels have been shown to induce 
mood symptoms (Stetler & Miller, 2011). Although the exact mechanism is unclear, 
effects on serotonin function are again thought to play a part as cortisol increases 
hepatic tryptophan 2,3-dioxygenase (TDO) enzyme activity, leading to reduction in 
tryptophan, reduction in serotonin and increasing levels of kynerenine, kynerenic acid 
and quinolonic acid (Maes et al., 1990, 2011). 
 
Interestingly, glucocorticoids are also known to have anti-inflammatory effects, which 
would contradict the hypothesis that they are involved in the inflammatory pathway 
that is responsible for the aetiology of mood symptoms. However, this is explained by 
the reduced hormone sensitivity and bioavailability of glucocorticoids while in an 
inflammatory state (Raison & Miller, 2003). Although serum cortisol levels increase in 
response to cytokines, it is proposed that the anti-inflammatory effect is suppressed 
because of cytokine-induced reduction in glucocorticoid receptor synthesis, 
translocation and binding. It is thought that cortisol still effectively activates TDO, thus 
decreasing serotonin levels and inducing mood symptoms (Maes et al., 2011). 
 
Pro-inflammatory cytokines also have effects on microglial cells, which may also 
contribute to the maintenance of mood symptoms. Microglia are the macrophage cells 
in the central nervous system and are activated by cytokines TNF-α and IL-1β (Harry & 








mood episodes (Stertz et al., 2013). Release of TNF-α and IL-1β can cause microglial 
activation and activation of neuronal apoptotic pathways to induce synaptic pruning 
(Kraft and Harry, 2011). Prolonged synaptic pruning and neuronal apoptosis may be 
pathologic, destroying functional neuronal pathways and inhibiting the formation of 
new pathways. This may manifest with neuropsychiatric symptoms including mood 
symptoms as seen in MDD, bipolar disorder and other psychiatric disorders (Paradise et 
al., 2012; Stertz et al., 2013).  
 
A raised inflammatory profile leading to a combination of serotonin dysfunction, 
disruption of the HPA axis and microglial activation may be responsible for impaired 
neuroplasticity leading to structural and functional brain changes in patients with mood 
disorders (Rosenblat et al., 2014; Miller & Raison, 2016). Although the underlying 
mechanism remains unclear, inflammation has been associated with structural and 
functional brain changes in humans including lateral ventricular enlargement, 
subgenual cingulate activity changes and decreased mesolimbic connectivity, all of 
which have also been implicated in the aetiology of MDD and bipolar disorder (Harrison 
et al., 2009; Kempton et al., 2011; Miller et al., 2013).  
 
1.4 The potential role of anti-inflammatory agents in mood disorders 
Given the substantial evidence linking the inflammatory cascade to mood disorders it 
would be logical to assume that the addition of an anti-inflammatory medication may be 
effective in the treatment of these conditions. Muller et al. were the first to demonstrate 
a reduction in depressive symptoms when using celecoxib, a COX-2 selective non-
steroidal anti-inflammatory drug, in addition to reboxetine, for the treatment of MDD in 
a double-blind, randomised, placebo-controlled pilot study (Muller et al., 2006). Since 
then, there have been numerous trials of anti-inflammatory agents in mood disorders 
and reviews and meta-analyses have suggested that anti-inflammatory medication may 
play an important role in the treatment of mood symptoms (Faridhosseini et al., 2014, 
Fond et al., 2014, Kohler et al., 2014, Ayorech et al., 2015, Rosenblat et al., 2016). There 








antidepressant properties (Kappelmann et al., 2016). However, most trials of these 
agents are limited by small sample sizes, short duration of follow-up and significant 
clinical heterogeneity.  
 
Warner-Schmidt et al. (2011) used the STAR*D dataset to determine whether 
nonsteroidal anti-inflammatory drugs (NSAIDs) could play a role in the treatment 
outcome of depressed individuals taking SSRIs and found that patients prescribed 
NSAIDs were more prone to be resistant to SSRI antidepressant medication. Thus, 
further work is needed in this area to clarify the role of inflammatory processes and 
anti-inflammatories in the treatment of mood disorders.     
 
1.5 Minocycline as a candidate treatment for depression 
As previously mentioned, numerous physiological mechanisms have been proposed to 
explain the link between inflammation and mood disorders, ranging from disturbed 
neurotransmission, disturbance in the biological mediators of stress (cortisol levels), 
activation of microglia and the release of neurotoxic metabolites leading to structural 
and functional brain changes. The tetracycline antibiotic minocycline has actions on a 
variety of these systems, although many of these are likely mediated through its anti-
inflammatory effects. These actions include anti-oxidant, anti-apoptotic, and modulation 
of glutamate and monoamine neurotransmission (Hashimoto & Ishima, 2010; 
Soczynska et al., 2012).  
 
Minocycline has a long half-life of 12–18 hours and is the most lipid-soluble of the 
tetracycline antibiotics, allowing for good penetration into the cerebrospinal fluid (CSF) 
and central nervous system (CNS) through the blood-brain barrier (Noble et al., 2009). 
It is usually well tolerated, has low propensity to produce antibiotic resistance and is 
commonly used to treat acne and other skin infections (Noble et al., 2009). It has been 
investigated in CNS diseases associated with inflammation such as multiple sclerosis, 
stroke and Parkinson's disease (Zhang et al., 2008; Zabad et al., 2007; Fagan et al., 2010 








have shown that a dose of 200mg daily in humans reduced the number of Gadolinium 
enhancing lesions in multiple sclerosis (Metz et al., 2004).   
 
Biological mediators of stress, such as glucocorticoids, and peripheral inflammation 
have been found to trigger neuroinflammatory processes, of which microglia are 
thought to exert a central role (Frank et al., 2015). Minocycline is an inhibitor of 
microglial activation (Soczynska et al., 2012) and in pre-clinical studies has been shown 
to decrease depressive and anxiety-like behaviours in mice whist reducing levels of pro-
inflammatory cytokines TNF-α and IL-1β. It has also been shown to normalise 
glucocorticoid levels through its actions on the HPA axis (Majidi et al., 2016). 
 
Another inflammatory pathway that has been implicated in the pathophysiology of 
depression is the kynurenine pathway. Minocycline acts on this pathway and has been 
shown to block IDO activation without changes in brain serotonin (O’Connor et al., 
2009). In a mice model of depression, minocycline has been shown to block the pro-
inflammatory cytokine TNF-α, which activates IDO (Liu et al., 2015). 
 
1.6 Rationale for a pilot RCT of minocycline for treatment-resistant depression 
Studies in animal models have shown that minocycline may induce antidepressant-like 
effects. In a study involving both independent and co-administration of minocycline in 
rats, minocycline was shown to be effective in the Porsolt swim test. This test is centred 
on a rodent's response to the threat of drowning, and the result have been interpreted 
as measuring susceptibility to negative mood. It is commonly used to measure the 
effectiveness of antidepressants. Sub-threshold doses of both antidepressants and 
glutamate antagonists in combination with sub-threshold doses of minocycline were 
also shown to have antidepressant effects when considering the Porsolt swim test 
(Molina-Hernández et al., 2008). 
 
In another pre-clinical study, learned helplessness was used as a model of depression 








rats treated with minocycline had improved performance on the conditioned avoidance 
test (mild foot shock) and this did not correlate to changes in locomotor activity. This 
suggests the effects of minocycline are antidepressant. The study found biological 
correlates with serotonin turnover in the orbitofrontal cortex; being increased in rats 
with learned helplessness and this was not altered by minocycline treatment. However, 
there were no changes to serotonin in other brain regions investigated. No changes to 
dopamine levels were reported although the data suggested decreased dopamine levels 
in rats who acquired learned helplessness. Interestingly, although no deficit in 
dopamine was reported, minocycline caused an increase in dopamine levels in the 
amygdala. Finally, BDNF levels were reduced following the acquisition of learned 
helplessness and these remained unchanged following minocycline treatment (Arakawa 
et al., 2012). 
 
In humans, there have been increasing data from open-label and pilot trials of 
minocycline use in psychiatric disorders, particularly in schizophrenia.  A meta-analysis 
of six RCTs (minocycline n=215, placebo n=198) demonstrated minocycline's 
superiority versus placebo for reducing endpoint Positive and Negative Syndrome Scale 
(PANSS) total scores (SMD=-0.59; CI 95%=[1.15, -0.03]; p=0.04), negative (SMD=-0.76; 
CI 95%=[-1.21, -0.31]; p=0.001); general subscale scores (SMD=-0.44; CI 95%=[-0.88, -
0.00]; p=0.05), Clinical Global Impressions scores (SMD=-0.50; CI 95%=[-0.78, -0.22]; 
p<0.001); and executive functioning (SMD=0.22; CI 95%=[0.01, 0.44]; p=0.04) in 
patients with schizophrenia (Solmi, 2017). All 6 studies included in this meta-analysis 
used minocycline 200mg/day as an augmentation strategy. 
 
Specific to mood disorders, data from an open-label study of patients with psychotic 
unipolar depression suggested that minocycline 200mg daily added to standard 
antidepressant treatment was effective and well tolerated (Miyaoka et al., 2012). More 
recently an open-label pilot study in individuals with bipolar depression showed that 
adjunctive minocycline 200mg daily led to a reduction in depressive symptom severity 








patients with unipolar depression (not necessarily treatment-resistant) receiving 
minocycline 200mg or placebo added to TAU found a 3-point change on the 
Montgomery-Asberg Depression Rating Scale (MADRS) in the minocycline group 
however this was not statistically significant. Nonetheless the minocycline group 
showed improvements in other outcomes suggesting that minocycline may be a useful 
adjunct to improve global experience, functioning and quality of life in depressed 
patients  
 
The available evidence implicating neuroinflammation as a neurobiological 
underpinning for depression suggests that the addition of an anti-inflammatory 
medication such as non-steroidal anti-inflammatory drugs (NSAIDs) may be effective in 
the treatment of depression and indeed recent meta-analyses have suggested as much 
(Faridhosseini et al., 2014, Fond et al., 2014, Kohler et al., 2014, Ayorech et al., 2015, 
Rosenblat et al., 2016). However, NSAIDs such as celecoxib are associated with serious 
cardiovascular and gastrointestinal side effects (Wolfe et al. 1999, Mukherjee et al., 
2011). Anti-cytokine drugs such as infliximab may also reduce severity of depressive 
symptoms in patients with a chronic inflammatory illness independently of 
improvement in physical illness treatment, but these drugs are also associated with 
potentially serious side effects and clinical trials in depressed patients are scarce 
(Kappelmann et al., 2016). Despite the potential antidepressant effects of minocycline, 
to date there have been no published clinical trials investigating the efficacy of 
minocycline in individuals with treatment-resistant depression. 
 
1.7 Aims of thesis:  
The aims of this thesis are: 
1. To evaluate current evidence on the efficacy and acceptability of anti-
inflammatory drugs in patients with major depressive disorder (MDD) and 
bipolar disorder.  
2. To determine whether the anti-inflammatory tetracycline antibiotic 








with treatment-resistant depression leads to an improvement in depressive 
symptoms and if so, to estimate effect sizes to inform the development of a 



































Chapter 2: Overview of Methods 
 
2.1 Introduction  
This thesis is a compilation of three original research papers and this section provides 
an outline of my involvement in the studies and a brief overview of the methods 
employed in the published studies. I have provided a rationale for the use of each 
methodology below however detailed descriptions and discussions of methods for 
individual studies are provided in the three successive chapters. 
 
The submission of the MD (Res) via publication is in accordance with King’s College 
London regulations and was approved by the MD (Res) sub-committee at initial 
registration. The research programme was monitored through formal three-monthly 
progress reports and approved by the MD (Res) sub-committee review panel in 2017 
based on an oral presentation of ongoing work, which covered the objectives, 
methodology and initial findings. The inclusion of specific publications from the related 
work was based on formal feedback and approval of the MD (Res) sub-committee. 
 
I began my research programme in 2014 and collaborated with colleagues at the Centre 
for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King’s 
College London as well as colleagues at the Pakistan Institute of Living and Learning to 
investigate the potential efficacy of anti-inflammatory agents in mood disorders. This 
thesis by publication contains the entire body of my research in this area, the majority 
of which was carried out between 2014 and 2017.   
 
2.2 Methodology to address Aim 1 
To determine the efficacy of anti-inflammatory drugs in improving both depressive and 
manic symptoms in patients with MDD and bipolar disorder a systematic review and 
meta-analysis of published randomised controlled trials of these drugs in patients with 
mood disorders was used. Systematic reviews and meta-analyses are the preferred 








bias and random error, to identify a full sample of primary studies that can be 
summarised to produce a reliable estimate of the pooled treatment effect (Cook et al., 
1997).   
 
Systematic reviews differ from narrative conventional reviews by the presence of a 
specific methodology that describes a search strategy, specific inclusion and exclusion 
criteria and methods of data synthesis (Oxman & Guyatt, 1993; Cook et al., 1997). Meta-
analysis is the method of data synthesis that allows the numerical pooling of results 
from multiple studies. Meta-analysis produces more precise estimates of the treatment 
effect than individual studies due to the larger sample sizes that result from pooling 
several trials. The larger sample sizes also lead to a reduction in random error (Higgins 
& Green, 2011).  
 
Meta-analysis also provides valuable information on the variation or heterogeneity 
between individual studies, which is important to consider when interpreting results. It 
is helpful to distinguish between different types of heterogeneity. Variability in the 
participants, interventions and outcomes studied is called clinical heterogeneity, while 
variability in study design and risk of bias is methodological heterogeneity (Higgins & 
Green, 2011). Variability in the treatment effects being assessed in different trials is 
known as statistical heterogeneity, and is due to clinical or methodological variability, 
or a combination of both. Statistical heterogeneity presents when the treatment effects 
are more different from each other than one would expect due to chance alone.  If there 
is evidence of significant statistical heterogeneity one can avoid pooling results and look 
for reasons for the heterogeneity, which could include methodological issues such as 
poor randomisation, early termination of trials, use of absolute rather than relative 
measures of risk, and publication bias (Higgins & Green, 2011).  
 
2.2.1 Analytic methods used for the meta-analysis: 
If all studies in the analysis were equally precise we could simply calculate the mean of 








to assign more weight to the studies that carried more information. This is what is done 
in a meta-analysis. Rather than calculate a simple mean of the effect sizes a weighted 
mean is calculated, with more weight given to some studies and less weight given to 
others. However there are different analytic methods for assigning the weight of each 
study. Statistical models for pooling effect sizes in a meta-analysis are generally based 
on fixed or random effects models. The two models make different assumptions about 
the nature of the studies, and these assumptions lead to different definitions for the 
combined effect, and different mechanisms for assigning weights to each study 
(Borenstein et al., 2007). 
 
The fixed effects model assumes that each study within a meta-analysis has the same 
underlying “true effect size” and that the combined effect is an estimate of this common 
effect size.  In contrast, the random effects model does not assume that each study has 
the same effect, and it is assumed that the studies are a random sample of the relevant 
distribution of effects, and that the combined effect estimates the mean effect in this 
distribution (Borenstein et al., 2007). The decision on which approach to use is 
important when pooling results from studies with significant heterogeneity.   
 
Under the fixed effect model all studies are estimating the same effect size, and so study 
weighting is determined entirely on the amount of information captured by that study. 
A large study would be given more weight, and a small study could be largely ignored. 
By contrast, the random effects model estimates the mean of a distribution of true 
effects. Large studies may yield more precise estimates than small studies, but each 
study is estimating a different effect size, and each of these effect sizes serve as a sample 
from the population whose mean we want to estimate. Therefore, as compared with the 
fixed effect model, the weights assigned under random effects can be considered more 
balanced. Large studies are less likely to dominate the analysis and small studies are 









Under the fixed effect model the only source of error in an estimate of the combined 
effect is the random error within studies. Therefore, with a large enough sample size the 
error will tend toward zero. This holds true whether the large sample size is confined to 
one study or distributed across many studies. By contrast, under the random effects 
model there are two levels of sampling and two levels of error. First, each study is used 
to estimate the true effect in a specific population. Second, all of the true effects are used 
to estimate the mean of the true effects. Therefore, the ability to estimate the combined 
effect precisely will depend on both the number of subjects within studies (first 
potential source of error) and also the total number of studies (second potential source 
or error). In other words, sample size does not affect the precision of the estimate of the 
mean in the random effects model (Borenstein et al., 2007). 
 
For the purposes of the current meta-analysis, it was determined that use of a random 
effects model would be most appropriate, as there was evidence of significant statistical 
heterogeneity between studies. Furthermore, the majority of studies were of small 
sample size and overall there were a low total number of studies for each meta-analysis, 
meaning that use of the fixed effects model would increase the chances of error.  
 
2.3 Methodology to address Aim 2 
To determine the potential efficacy of minocycline as an adjunct to treatment as usual 
(TAU) in patients with treatment-resistant major depressive disorder, a 12-week, 
double blind, randomised, placebo-controlled pilot trial was conducted. Randomised 
controlled trials (RCTs) are the most appropriate study design to determine whether a 
cause-effect relation exists between treatment and outcome (Sibbald & Roland, 1998). 
The standard RCT in mood disorders compares the efficacy of a specific treatment with 
that of placebo for subjects identified according to prior criteria. It uses the parallel 
comparison of one or more treatments with placebo, with sample sizes considered 
adequate to detect a therapeutic signal, given the expected placebo response rates in 
that specific population (Tohen et al., 2015). Sample sizes are usually calculated using 








When a true population effect size is unknown due to a paucity of trials of a particular 
treatment, pilot RCTs are often used to estimate effect sizes. Pilot RCTs are those studies 
in which the future, larger, hypothesis-testing RCT is conducted on a smaller scale 
(piloted) to see if it can be done (Eldridge et al., 2016). Pilot studies focus on the 
processes of the main study, for instance to determine whether recruitment, 
randomisation, treatment, and follow-up assessments all run according to protocol. 
They are also important in providing proof-of-concept and preliminary efficacy data to 
provide support for further phase II RCTs.  
 
2.3.1 Analytic methods used for the RCT: 
Since the validity of RCTs depends greatly on their design, conduct and reporting, it is 
important to use appropriate statistical methods when analysing the data from these 
studies. With regards to clinical trials six specific statistical issues need to be considered 
when developing a statistical analysis plan: baseline comparability of groups, selection 
of covariates for adjustment, covariate adjustment, intention-to-treat analysis (ITT), 
subgroup analysis and the handling of missing data. I will discuss how each of these 
issues were addressed for the pilot RCT included in this thesis.  
 
2.3.1.1 Baseline Comparability  
It has been argued that randomisation guarantees unbiased allocation of treatments to 
study participants but does not ensure for a particular trial that the patients or study 
participants in each treatment group will have similar characteristics (Altman, 1991). 
This suggests that randomisation gives unbiased treatment allocation, but not 
necessary balance. Some important covariates may not be balanced between treatment 
groups after randomisation, especially when the sample size is small and therefore 
usual practice in published clinical trial reports is to present baseline information on 
prognostic factors, as we have done for the included pilot RCT. Tests of significance that 
utilize a P-value to determine the statistical significance of the observed baseline 
difference in patients’ characteristics are sometimes reported however this has been 








comparison of patients’ characteristics appears to be that researchers should present 
the distributions of such baseline information of treatment groups in a table allowing 
readers to see the extent of similarities of the groups (Egbewale, 2015). We used this 
approach for summarizing baseline demographics and clinical data in the pilot RCT 
report.  
 
2.3.1.2 Selection of covariates for adjustment 
In order to account for baseline imbalances between treatment groups it is important to 
use an appropriate statistical method to adjust for covariates. The decision on which 
covariates to include often relies on the use of baseline tests of significance. In this case, 
study groups are compared in a wide range of baseline variables; those with statistically 
significant difference between groups are automatically accounted for in the analysis, 
and those that are not significant are ignored. Although this approach was commonly 
used previously, in recent years its use has been discouraged (Frayers and King, 2000) 
because it has been argued that following a robust randomisation process, it would 
appear redundant to again test whether the observed difference is purely by chance or 
not, which is what the test of significance does. Furthermore, disregarding baseline 
covariates that have prognostic influence but that are not significantly different 
between groups is also an argument against the use of hypothesis testing approach for 
covariate selection (Egbewale et al., 2014) since a significant imbalance will not matter 
if a factor does not predict outcome; whereas, a non-significant imbalance can benefit 
from covariate adjustment (Egbewale et al., 2014). 
 
An important consideration for selection of covariates is prognostic strength and there 
are two ways in which this can be assessed. The first approach is to determine the 
prognostic importance based on the level of correlation between the particular 
covariate and the outcome variable with usual practice being that, if there is a weak 
correlation (r < 0.3), adjusting for the imbalance in such a covariate is not necessary 
even with a significant baseline difference in the covariate between the treatment 








and the outcome variables requires analysis of correlation between the covariates and 
the outcome of interest before deciding on selection of such covariates for adjustment. 
 
The other approach when considering the prognostic importance of covariates is to 
include those that have been found a priori to be prognostic in relation to the outcome 
variable. This includes evidence of suitable covariate-outcome correlation (r ≥ 0.3) from 
previous research (Egbewale et al., 2014). The decision on which covariate is selected 
for adjustment is taken before the trial starts and is specified in the protocol. 
Adjustment of covariates identified a priori also includes statistically adjusting for 
stratification or minimisation factors. For the purposes of the pilot RCT, we had decided 
on inclusion of some variables a priori, although these were not listed explicitly in the 
published protocol.  These included baseline outcome scores, treatment contrast 
(minocycline or placebo), time and interactions between time and treatment to allow 
treatment estimates to differ at 2, 4, 8 and 12 weeks.  
 
2.3.1.3 Covariate adjustment 
Randomisation may not ensure balance in some important covariates which may make 
it difficult to interpret the results of statistical tests for the treatment effect (Tu et al., 
2004). Thus, it is important that any imbalances are corrected or adjusted. Methods for 
controlling the covariate imbalance can either be at the design stage or during statistical 
analysis. Adjustment at the design stage includes the use of minimisation and 
stratification. Adjustment during statistical analysis is carried out by using relevant 
statistical analysis models. Many clinical trials use both design methods that reduce 
covariates imbalance and statistical adjustment during analysis simultaneously. 
 
In the case of a single post-treatment assessment of a continuous outcome variable, 
methods for adjustment at the statistical analysis stage include: 1) change score analysis 
that determines group effect based on the difference between the baseline and the post 
treatment score (basic adjustment) 2) analysis of covariance, which is a model-based 








adjustment can also be performed by the use of logistic regression or by pooling the 
stratified analyses, using, for example, a Mantel Haenszel test (Egbewale 2015). 
Statistical adjustment achieves more valid treatment effect estimates and significance 
tests (Assmann et al., 2000). 
 
Although the main reason for adjustment of covariates is to minimise the occurrence of 
a chance finding, it may also lead to greater power of the trial (Egbewale et al., 2014). In 
our pilot RCT  all continuous measures, including the primary outcome HAMD scores 
were analysed with linear mixed models to account for the dependencies in the data 
from the repeated measures. CGI was an ordinal outcome and so a generalised linear 
mixed model (proportional odds) was used for this outcome. Explanatory variables in 
the model were baseline outcome scores, treatment contrast (minocycline or placebo), 
time and interactions between time and treatment to allow treatment estimates to 
differ at 2, 4, 8 and 12 weeks. 
 
2.3.1.4 ITT analysis 
Intention-to-treat (ITT) analysis is the strategy for the analysis of RCTs that compares 
participants in terms of the groups to which they were originally randomly assigned 
(Hollis and Campbell, 1999) meaning that participants are always analysed in the group 
to which they were initially randomised even if they drop out of the study (Hollis and 
Campbell, 1999). ITT analysis is widely considered as the most appropriate analysis set 
for the primary effectiveness analyses of any phase III clinical trial since it assesses the 
overall clinical effectiveness most relevant to the real-life use of the intervention. 
 
The Consolidated Standard of Reporting Trials (CONSORT) statement recommends that 
authors should indicate whether analyses were performed on an ITT basis (Begg et al., 
1996) and we ensured that we followed this guideline when conducting the pilot RCT. 
The most appropriate way to deal with all forms of protocol violation is to apply ITT to 
include patients who receive a treatment other than the one allocated, and patients who 








Per-protocol analysis is another method used (often as a secondary evaluation) in 
which participants who have not adhered to the allocated intervention are excluded. It 
only describes the outcomes of the participants who adhered to the research protocol. 
Per-protocol analysis is problematic when the reasons for non-adherence to the 
protocol are related to prognosis (Montorri and Guyatt, 2001). We know that 
participants who adhere to treatment tend to do better than those who do not adhere, 
even after adjustment of co-variates, therefore excluding participants that do not 
adhere from the analysis leaves only those who are likely to have a better outcome and 
leads to bias.  
 
2.3.1.5 Subgroup analysis 
Subgroup analyses allow comparisons of treatment outcomes for participants 
subdivided by baseline strata to determine whether treatment difference in outcome 
(or lack of it) depends on certain characteristics of participants. Subgroup analyses are 
important if there are potentially large differences between stratified groups in the risk 
of a poor outcome with or without treatment, if there are practical questions about 
when to treat, or if there are doubts about benefit in specific groups (e.g. the elderly). 
Since participants recruited into a clinical trial are not a homogeneous sample, their 
response to treatment and the differing impact on them of different treatments may 
vary, in ways that influence choice of treatment (Pocock et al., 2002).  
 
However, most trials only have sufficient statistical power to detect the overall main 
effect difference in response between treatment groups, so that if subgroup effects do 
exist, they may well go undetected because the trial was not large enough (Pocock et al., 
2002). Smaller sample sizes within subgroups lead to greater standard errors and 
reduced power relative to the overall clinical trial, resulting in an increased risk of a 
type II error; whereas, the multiplicity of hypotheses tests that results from examining 
multiple subgroups will lead to an increased risk of a type I error (Altman, 1991). The 
suggested approach to a sub-group analysis is to compare the difference between the 








model. We had initially planned on conducting a subgroup analysis of differences in 
biomarker levels between the minocycline group and the placebo group in our study, 
however given the amount of missing biomarker data, the analysis of biomarkers was 
restricted to a descriptive analysis only.  
 
2.3.1.6 Handling missing data  
Even in a well-designed and controlled study, missing data occurs in almost all research. 
Missing data present various problems. First, the absence of data reduces statistical 
power. Second, the lost data can cause bias in the estimation of parameters. Third, it can 
reduce the representativeness of the samples. Fourth, it may complicate the analysis of 
the study. Each of these issues can damage the validity of the trials and can lead to 
invalid conclusions. 
 
Rubin (1976) first described and divided the types of missing data according to the 
assumptions based on the reasons for the missing data. In general, there are three types 
of missing data according to the mechanisms of missingness. 
 
 
i. Missing completely at random 
Missing completely at random (MCAR) is defined as when the probability that the data 
are missing is not related to either the specific value which is supposed to be obtained 
or the set of observed responses. The statistical advantage of data that are MCAR is that 
the analysis remains unbiased. Power may be lost in the design, but the estimated 
parameters are not biased by the absence of the data. 
 
ii. Missing at random 
Data are regarded as Missing at random (MAR) when the probability that the responses 
are missing depends on the set of observed responses, but is not related to the specific 
missing values which is expected to be obtained. This is the assumption that was 








iii. Missing not at random 
If the characters of the data do not meet those of MCAR or MAR, then they fall into the 
category of missing not at random (MNAR). The cases of MNAR data are problematic. 
The only way to obtain an unbiased estimate of the parameters in such a case is to 
model the missing data. The model may then be incorporated into a more complex one 
for estimating the missing values. 
 
The best possible method of handling the missing data is to prevent the problem from 
occurring in the first place by well-planning the study and collecting the data carefully. 
However when data is missing despite these efforts, statistical methods such as the Last 
Observation Carried Forward (LOCF), Multiple Imputation and Maximum Likelihood 
approach can be used. For the pilot RCT, our statistician used the Maximum Likelihood 
approach to handle missing data. This method does not impute any data, but rather uses 
each cases available data to compute maximum likelihood estimates. The maximum 
likelihood estimate of a parameter is the value of the parameter that is most likely to 
have resulted in the observed data (Hox, 1999). 
 
When data are missing, we can factor the likelihood function. The likelihood is 
computed separately for those cases with complete data on some variables and those 
with complete data on all variables. These two likelihoods are then maximized together 
to find the estimates. This method gives unbiased parameter estimates and standard 
errors but an advantage over Multiple Imputation is that it does not require the careful 
selection of variables used to impute values that Multiple Imputation requires (Hox, 
1999). By using the likelihood approach in the analysis of the data from the pilot RCT, 
we found that socio-economic status at baseline was a predictor of missingness of 









2.4. Contribution to each published peer-reviewed paper 
2.4.1 Paper 1: Husain MI et al. (2015) Minocycline as an adjunct for treatment-
resistant depressive symptoms: study protocol for a pilot randomised controlled 
trial. Trials, Sep 15;16:410. doi: 10.1186/s13063-015-0933-5.  
This is the published study protocol for the pilot randomised controlled trial of 
minocycline as an adjunct for treatment-resistant depressive symptoms. I drafted the 
protocol for the trial under the supervision of my supervisors. The development of the 
protocol helped inform the completion and submission of the ethics application, which 
was approved in March 2014. Following ethical approval, I registered the trial on 
Clinicaltrials.gov and as first author, wrote the manuscript for this paper.   I submitted 
the manuscript and made all necessary amendments that were suggested following a 
detailed peer review process, under the guidance of my supervisors, Professors 
Chaudhry and Young. The protocol was also presented as a poster at the International 
Society of Bipolar Disorders annual meeting in Toronto, Canada in June 2015. 
 
2.4.2 Paper 2: Husain MI et al (2017) Anti-inflammatory treatments for mood 
disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 
Sep; 31(9):1137-1148. doi: 10.1177/0269881117725711. Epub 2017 Aug 31. 
For the systematic review and meta-analysis, I developed a study protocol under the 
supervision of Professor Allan Young. This was registered on the PROSPERO database 
for systematic review protocols. I then undertook a systematic search of relevant 
databases using the search criteria in the protocol. After searches were complete I 
scanned abstracts of potentially relevant studies and used the study inclusion and 
exclusion criteria to shortlist papers. If a second opinion was required regarding a 
study's inclusion, this was sought from my co-authors. After shortlisting studies I 
constructed tables to extract data pertaining to the primary and secondary outcomes 
from each study. This was done in collaboration with one co-author (Rebecca 
Strawbridge). Two co-authors (Professor Young and Dr. Paul Stokes) completed the 








Revman software to conduct a quantitative meta-analysis. My co-author Rebecca 
Strawbridge undertook meta-regression analysis and supported me with measurement 
of publication bias. As first author I wrote the manuscript for the review and submitted 
the paper for publication. In collaboration with my co-authors I made necessary 
corrections to the manuscript after the peer review process.  
 
2.4.3 Paper 3: Husain MI et al. (2017) Minocycline as an adjunct for treatment-
resistant depressive symptoms: A pilot randomised placebo-controlled trial. 
Journal of Psychopharmacology, Sep;31(9):1166-1175. doi: 
10.1177/0269881117724352. Epub 2017 Aug 31. 
This was a multi-site, 12-week, individually randomised, parallel group, double blind, 
placebo-controlled, pilot trial of minocycline added to treatment as usual for patients 
suffering from a DSM-5 major depressive episode that had failed to respond to at least 
two antidepressant treatments. The study was conducted in Karachi, Pakistan, and 
participants were recruited from outpatient psychiatric clinics at Abbasi Shaheed 
Hospital, Karwan-e-Hayat Hospital, Civil Hospital, and the Institute of Behavioural 
Sciences between October 2014 and March 2016.  
 
My role as chief investigator in this study was to provide scientific leadership and 
oversight to the research team in conjunction with my supervisors. As mentioned 
previously I developed the protocol for the study, completed and submitted the 
application for ethical approval and registered the study to a clinical trial database. I 
chaired bi-weekly Skype meetings to provide supervision to the research assistants and 
trial managers. Along with my supervisors I provided research training and workshops 
to the research team during annual visits to Pakistan. Once data collection was 
complete, I worked with my co-author, Dr John Hodsoll to analyse the data. I was also 
involved in dissemination of the findings from this study and submitted a poster of 
preliminary results at the joint International Society of Bipolar Disorders/International 
Society of Affective Disorders biennial meeting in Amsterdam, Netherlands in July 2016. 








publication. After a rigorous peer review process, I worked on amendments to the 













































































































































































































































































Chapter 6: Discussion  
 
6.1 Strengths and limitations of systematic review and meta-analysis 
Previous meta-analyses of anti-inflammatory treatments in mood disorders have only 
evaluated the efficacy of these compounds for a specific disorder (e.g. bipolar disorder 
or MDD), and only for depressive symptoms (Kohler et al., 2014, Rosenblat et al., 2016). 
As far as I am aware, this is the first meta-analysis that has assessed anti-inflammatory 
treatments for mania. Furthermore, by combining studies of both bipolar and unipolar 
depression the current review may have the advantage of investigating inflammation as 
a trans-diagnostic target for multiple neuropsychiatric disorders; few studies have 
directly compared inflammation in unipolar and bipolar depression but there do not 
appear marked differences between these subpopulations (Su et al., 2011, Goldsmith et 
al., 2016) and increases in statistical power can be achieved by considering the two 
together. 
 
The benefit of combining studies in BD and MDD is limited by the inability to truly pool 
the data of all studies. In the current review, studies were pooled based on whether they 
reported post-treatment depression scores or change in depression scores, but this 
approach makes it difficult to ascertain what the actual pooled effect size is.  A study 
reporting change versus post-treatment scores should not be a differentiating factor 
that would mediate effect size, assuming randomization and blinding was effective.  
Despite this, we were unable to pool standard mean differences (SMDs) from all studies 
in unipolar and bipolar depression because not all of them used the same symptom 
rating scales and the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins & Green, 2011) recommends only pooling change in symptom scores with 
post-symptom severity measures into one mean difference analysis if the same rating 
scale is used in all studies, which was not the case for trials included in our review.  
Therefore, the pooled SMDs reported in this meta-analysis may not be indicative of the 









Other limitations of the systematic review include the small sample sizes in the majority 
of studies included, with most showing only small to medium effect sizes with high 
heterogeneity. It is worth mentioning that a large study of N-acetylcysteine for the 
treatment of MDD (Berk et al., 2014) had to be excluded from the meta-analysis because 
full results could not be obtained despite efforts to contact the authors. This study was 
negative, and had a larger sample size than all six of the studies in the depression meta-
analysis combined. It is likely that exclusion of this study has skewed the reported 
pooled SMD in the meta-analysis of anti-inflammatory treatments for depressive 
symptoms. The study by Dean et al. (2017) of minocycline as an adjunct for patients 
with MDD was published after our final search was completed, but if we had included 
this along with the findings of our pilot RCT in treatment-resistant depression, it is 
unlikely to have influenced the pooled SMD, given the small sample sizes in both trials 
and the statistical heterogeneity between studies.  
 
Although there was no evidence of publication bias, this was not assessed statistically 
due to small numbers and sizes of studies included. Furthermore, treatment durations 
tended to be short, mostly ranging from 6 to 12 weeks, which means there is no data on 
long-term adverse effects, tolerability and efficacy of anti-inflammatory treatment. 
Although efforts were made to summarize adverse effects of the anti-inflammatory 
interventions, not all studies reported these, limiting a full evaluation of the safety and 
tolerability of these interventions. It is also important to note that the antidepressant 
effect of the interventions may be mediated via their effects on physical health 
comorbidities, although only three studies in which patients recruited were diagnosed 
with physical health comorbidity were included in the meta-analysis. Finally, the 
generalizability of 9 studies’ findings included in this systematic review is potentially 
questionable since these trials were all conducted in Iran and trials in high-income 











6.2 Strengths and limitations of pilot randomised controlled trial 
To our knowledge, this is the first RCT of minocycline in patients with treatment-
resistant depression (TRD). For the purposes of the trial, treatment resistance was 
defined as failure to respond to at least two antidepressant medications during the 
current episode of illness. This definition for TRD was also used by the authors of a 
large systematic review of 42 randomised trials to reflect the consensus within the 
literature (Berlim et al., 2007) and in the World Federation of Societies of Biological 
Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive 
disorders (Bauer et al., 2002). The trial was conducted in Pakistan, in collaboration with 
investigators from the UK. There is a dearth of high quality trials from low and middle-
income countries and such studies from these countries should be encouraged.  
 
The findings of the pilot study show that minocycline may be effective as an adjunct to 
treatment as usual in patients with treatment-resistant depressive symptoms. 
Participants randomised to minocycline showed a significant response and the 
estimated mean reduction in HAMD scores was 18 points. The standardized effect size 
of 1.21 is large; an effect size of 0.40 or higher has been considered a clinically 
significant response criterion in previous clinical trials of antidepressant treatments 
(Faries, 2000). The intervention was also well tolerated in comparison to placebo and 
there was no significant difference between groups in terms of frequency of adverse 
events. Most participants in both the minocycline and placebo groups were receiving a 
SSRI antidepressant as part of their usual treatment. Most participants were also using 
an augmenting agent (either a second antidepressant or an antipsychotic). The duration 
since starting their first treatment for depression was over one year for most 
participants, which suggests that their symptoms were indeed significantly treatment 
refractory. We did not include a symptom severity threshold requirement for inclusion 
into the trial as high entry criteria requirements have been associated with greater 
placebo response rates, and can cause raters to overestimate severity of symptoms at 









The results of our pilot add to the growing evidence that minocycline may have 
antidepressant properties. Open-label studies of minocycline augmentation for unipolar 
depression have supported this claim (Miyaoka et al., 2012). A more recent RCT of 
minocycline monotherapy in patients with a HIV diagnosis and mild to moderate 
depression (HAMD < 18) found significantly greater improvements in HAMD scores in 
patients in the minocycline group compared to those in the placebo group. There were 
also more partial responders in the minocycline group compared to the placebo group 
(Emadi-Kouchak et al., 2016). Another open-label study of minocycline added to 
treatment as usual (TAU) in 29 patients experiencing a DSM-IV-TR major depressive 
episode with a diagnosis of bipolar I or II disorder, found that adjunctive minocycline 
was associated with a reduction in depressive symptom severity from baseline to week 
8 on the Montgomery-Asberg Depression Rating Scale (MADRS) scores (P<0.001, 
d=0.835), HAMD-17 (P<0.001, d=0.949) and CGI-S (P<0.001, d=1.09). Improvement in 
psychomotor speed, but not verbal memory or executive function, was observed only 
amongst individuals exhibiting a reduction in depression severity (P=0.007, d=0.826). 
Analysis of biomarkers in this study showed that levels of IL-12/23p40 (P=0.002) were 
increased, while levels of IL-12p70 (P=0.001) and C-C motif chemokine ligand 26 
(CCL26) (P<0.001) were reduced from baseline to week 8. A reduction in CCL26 levels 
was associated with a less favourable treatment response (P<0.001) (Soczynska et al., 
2017).  
 
A study by Dean et al. (2017) also published after the included systematic review was in 
press, provides more evidence that minocycline may play a role in the treatment of 
depressive illness. In this 12-week RCT, a total of 71 adults with unipolar DSM-IV major 
depressive disorder were randomised to minocycline 200mg daily added to TAU or 
placebo added to TAU. The participants recruited to this study did not need to meet 
criteria for treatment resistance. Although the results revealed no significant difference 
in the primary outcome (MADRS scores) between groups, there were significant 
differences on secondary outcome measures. At week 12, the minocycline group 








effect size (ES) (95% confidence interval) = -0.62 [-1.8, -0.3], p = 0.02; Quality of Life 
Enjoyment and Satisfaction Questionnaire score - ES = -0.12 [0.0, 0.2], p < 0.001; and 
Social and Occupational Functioning Scale and the Range of Impaired Functioning Tool 
score – ES = 0.79 [-4.5, -1.4], p < 0.001. These effects remained at the follow-up (week 
16), and Patient Global Impression also became significant, ES = 0.57 [-1.7, -0.4], p = 
0.017 (Dean et al., 2017).  
 
The findings of the study by Dean and colleagues may differ from ours because of the 
clinical characteristics of the participants included. Our study included only participants 
that had failed to respond to at least two antidepressants within the same episode and 
as such, the results may indicate that minocycline may be more effective for those 
patients that have a degree of treatment resistance. It has been hypothesized that a sub-
group of patients with TRD have an underlying activated inflammatory response, with 
studies showing that TRD patients have activation of monocytes and microglia, which 
leads to increased production of pro-inflammatory cytokines (e.g. IL-6 and TNF-α) and 
acute-phase proteins (i.e. CRP) (Grosse et al., 2016, Strawbridge et al., 2015). Given its 
broad anti-inflammatory actions on these pathways, minocycline may inhibit the 
inflammatory response more effectively in TRD patients leading to greater 
improvements in mood compared to those patients that are not treatment resistant. 
 
However, the results of the pilot trial should be considered under the light of certain 
limitations. One of the main concerns about the findings was the discrepancy between 
the primary outcome measure i.e. HAMD scores and the secondary outcome, the 
patient-rated PHQ-9. There was large statistically significant response on the clinician-
rated HAMD and CGI measures in the minocycline group but a smaller response on the 
PHQ-9, which was not statistically significant. In the placebo group, there was no 
response on the HAMD and CGI measures but a large response on the PHQ-9. The 
absence of a response as measured by HAMD scores in the placebo group may reflect 
the chronicity and initial severity of the sample. A total of 95% of the participants 








Studies have indicated that the natural history of illness and specifically, longer 
duration of current illness can reduce the placebo response (Rutherford & Roose, 2013). 
Secondly it has been found that placebo response decreases with increasing severity of 
baseline depression scores, with a recent study finding that placebo response 
significantly declined as baseline HAMD increased (particularly as it exceeded a score of 
25) (Fournier et al., 2010). The mean baseline HAMD score in the placebo group in the 
current study was 32.6 with only 3 participants scoring less than 25.  
 
Lack of correlation between clinician and patient-rated outcomes are not uncommon 
and previous larger trials of antidepressant treatments have also reported similar 
discrepancies (Targum et al., 2013). The reasons for the discrepancy in this pilot trial 
are unclear although participant motivation to be involved in the trial, a heightened 
awareness of symptoms at baseline, and the experimental environment itself (i.e. 
expectancy biases) may have affected the patient's perception of depressive symptoms 
and influenced self-rating during the study. It is also prudent to consider the robustness 
of blinding during the study; although every attempt was made to maintain a strong 
blind, this was not formally measured. The degree of discrepancy between outcome 
measures in the context of a small sample size could raise questions about the success 
of blinding and potential measurement bias. Inter rater reliability was not formally 
measured and recorded although Masters level clinical psychologists, who were trained 
by local principal investigators, carried out all assessments.  
 
Another potential limitation of the study is that all participants recruited to the study 
were permitted to change their regular medications under the supervision of their 
treating team. Although it can be argued that changes to TAU would add “noise” to the 
treatment signal, we were able to record all medication changes for each participant 
and found that these changes were similar between the groups. However, the fact that 
we did not measure medication adherence is a shortcoming of the study. Future trials 








scales such as the Morisky measurement of medication adherence (MMAS-4) (Morisky, 
1986). 
 
This study was designed as an exploratory, pilot RCT and for studies of this nature the 
sample size is appropriate (Julious, 2005; US FDA 2016). Nonetheless the small sample 
size means that any estimates of effect are unlikely to be robust. The small sample size 
also limits the evaluation of how representative the sample is and also the 
comparability of the two treatment arms.  The generalizability of our results is limited 
by the fact that this was a single centre study conducted in Karachi, Pakistan. Larger, 
multi-centre studies in other settings are required to determine whether our findings 
are applicable to other populations, particularly those in high-income countries. Lastly, 
this was only a 12-week study and since participants were followed up for a relatively 
short period of time, we are unable to comment on the long-term efficacy and safety of 
minocycline as an augmenting agent in treatment-resistant depression. 
 
6.3  Issues related to conducting clinical trials in a low and middle-income country 
In this section I will discuss factors that may make conducting a clinical trial in a low 
and middle-income country (LAMIC) such as Pakistan, different from conducting trials 
in higher-income countries. Since there is a paucity of data on Pakistan-specific 
demographics or national epidemiologic studies conducted with any standardized 
diagnostic interviews, this discussion is narrative and based on my experience during 
the pilot study.  
 
It is important to recognize the benefits of conducting clinical trials in LAMIC. As 
mentioned previously there is a dearth of literature from these regions and more 
studies should be encouraged for several reasons. Firstly, it has been reported that it 
may be easier to detect a signal in clinical trials and to separate the signal from ‘noise’ in 
the analysis of data from a LAMIC. This is thought to occur due to cultural and religious 
factors, that lead to patients with severe mental illness in countries like Pakistan being 








misuse, which would make the sample diagnostically cleaner (Andrade, 2013). 
Furthermore, research participants in Pakistan usually have strong family support, and 
family members tend to ensure medication adherence and often bring participants to 
follow-up appointments. This helps maintain adherence to the study protocol and 
maintains high study retention rates, as in the case of our pilot trial, in which the 
attrition rate was only 17%.  
 
Other advantages of conducting trials in LAMIC include the practical benefits for the 
investigators. These countries are densely populated; recent census results from 
Karachi, the city where our study was conducted, revealed a population of 14.9 million 
although these results have been widely disputed and the actual figure is more likely to 
be over 20 million (Rana, 2017). Such large populations put huge pressure on local 
healthcare systems to cater to the needs of people with mental illness and so 
recruitment targets in clinical trials are met with greater speed. In addition, salaries, 
cost of living and clinical trial expenses are much lower, so trials can be conducted with 
more modest funding. As patients are used to a paternalistic model of healthcare, 
dropout rates are often lower than in other regions. Another important advantage to 
researchers is that in countries such as Pakistan almost all investigators and research 
personnel are fluent in English, which is the language in which study protocols are 
drafted. 
 
Clinical trials conducted in LAMIC are also important as they contribute to significant 
capacity building. The local study team is trained in Good Clinical Practice and research 
processes, which empowers local academic centers to design and conduct their own 
studies. Patients that participate in trials also gain because they receive high quality, 
individualized care and follow-up at no cost and often have their travel expenses for 
assessment visits reimbursed. Finally, the broader society within LAMIC also benefits 
from such trials because locally relevant pharmacodyanmic and pharmacokinetic data is 









However, there are also important challenges to address when conducting trials in 
LAMIC. The aforementioned pressure on local health services and in particular, the 
scarcity of mental health services in countries like Pakistan, may contribute to larger 
effect sizes in clinical trials, which means that these have to be interpreted with some 
caution as findings may not be replicable in high-income countries. Other challenges 
include the translation of consent forms and rating scales, which is sometimes done 
with only superficial validity and without confirming the psychometric properties of the 
translated scales. Given the poor literacy rates in countries such as Pakistan, research 
participants who have lower literacy and education levels are at risk of exploitation. We 
overcame this issue by ensuring that the research team explained the study to all 
participants in the presence of a witness (usually a care giver) and allowed them up to 
24 hours to take the study information sheet home and discuss their participation with 
relatives and friends before providing consent. Literate participants signed the consent 
forms but, if the participant could not write their name, they placed a thumbprint on the 
consent form, which was countersigned by the witness. This approach is not standard 
practice in all settings and is not deemed mandatory by regulatory bodies. Another 
important challenge that we and other researchers have faced when conducting trials in 
countries such as Pakistan is the considerable cultural and psychological significance 
that participants place on drawing of blood samples, especially if this involves storage of 
samples for later analysis. Several participants in our pilot study refused to consent to 
drawing of blood samples, which made it impossible to draw inference of any 
mechanistic hypothesis on the mode of action of minocycline from the limited 
biomarker data that was analyzed.  Such challenges must be taken in to account when 
designing clinical trials in LAMIC and perhaps it would be more appropriate that the 
provision of blood samples be stipulated as a requirement for recruitment if the study 
has a mechanistic component that requires the evaluation of biomarkers. 
  
6.4 Potential mechanisms of minocycline’s putative antidepressant action 
Since it has been postulated that the potential antidepressant mechanisms of action of 








Erythrocyte Sedimentation Rate (ESR) and C-reactive protein (CRP) levels at baseline 
and at the end of treatment. Both biomarkers have been shown to be reliable indicators 
of systemic inflammation (Cameron & Kelvin, 2000). Unfortunately, in the included pilot 
study many participants refused to consent to the provision of blood samples. This may 
be due to cultural factors and the religious significance of drawing blood, particularly 
during religious periods such as the month of Ramadan. I have conducted analysis of the 
biomarker data that was available but given the small sample size and amount of 
missing data, drawing any inference from these results would be unwise.  The missing 
data is due in part to the limited funding for the study, which did not allow for assertive 
follow-up of participants to ensure bloods were drawn at both baseline and end-point. I 
will try and address this in the planned replication study, which I hope will have more 
substantial funding. Future studies of minocycline should also include measurement of 
inflammatory cytokines such as IL-6 and TNF-α, amongst others, to determine the 
association between changes in inflammatory biomarkers and improvement in 
depressive symptoms. 
 
As summarized earlier, inflammation has been shown to cause serotonin dysfunction, 
disturbances in the HPA axis, microglial activation and the release of neurotoxic 
metabolites leading to neuroplastic changes. All of these factors may be involved in the 
manifestation of a depressive syndrome. I hypothesize that minocycline acts on several 
of these mechanisms to produce an antidepressant effect. I have previously summarized 
evidence that shows how microglia plays a significant role in the neuroinflammatory 
processes that are implicated in the aetiology of depression. Minocycline has shown to 
be an inhibitor of microglial activation (Soczynska et al., 2012) and has also shown to 
decrease depressive and anxiety-like behaviours in mice whilst reducing pro-
inflammatory cytokines (i.e. TNF and IL-1B) and glucocorticoids (Majidi et al., 2016). 
The kynurenine pathway, another inflammatory pathway purported to play a part in 
the pathophysiology of depression, is also modulated by minocycline. Pro-inflammatory 
cytokines can activate the enzyme indoleamine 2,3-dioxygenase (IDO). Increased IDO 








pro-depressant and neurotoxic metabolites (Grosse et al., 2016). In animal studies, 
minocycline has been shown to block the pro-inflammatory cytokine TNF-α, which 
activates IDO (O’ Connor et al., 2009, Liu et al., 2015).  
 
Another important consideration when examining minocycline’s putative 
antidepressant action is its pharmacokinetic properties and possible interactions with 
antidepressant drugs. There is limited data on the metabolism of minocycline (Nelis & 
de Leenheer, 1982) but it is plausible that it is mediated by Cytochrome P450 enzymes, 
which are involved in the metabolism of many commonly used antidepressants. 
Further, recent in vitro studies indicate that minocycline may exert local inhibition of 
cytochrome p450 enzyme activity in neuronal cells (Regen et al., 2016). If minocycline 
does inhibit one or more cytochrome p450 enzymes either by competition for 
metabolism or a direct mechanistic effect, it may also be contributing to enhanced 
antidepressant activity by increasing the plasma or local concentration of 
antidepressant drugs. 
 
In addition to its anti-inflammatory and pharmacokinetic properties, minocycline has 
been shown to be neuroprotective and may directly promote neurogenesis (Soczynska 
et al., 2012). These neuroprotective and neurotrophic properties may also be involved 
in its potential antidepressant actions. Studies have shown that minocycline increases 
the number of integrated newborn hippocampal neurons by promoting the survival of 
newly divided cells (Liu et al., 2007), and that it also increases the survival of neurons in 
animal models of ischemia (Yrjanheikki et al., 1998). Other animal studies have 
reported that minocycline reduces tissue damage and cavitation after spinal cord injury 
(Festoff et al., 2006), and restores impaired hippocampal neurogenesis after 
lipopolysaccharide (LPS)-induced inflammation (Ekhdal et al., 2003).  
 
Although the exact mechanisms by which it affects neurogenesis and neuroprotection 
remain unknown, it has been shown to modulate systems (e.g. inflammation) that affect 








and function in response to environmental demands. Mood disorders are marked by 
abnormalities in brain structure and function, as well as impairments in cognition 
(Kempton et al., 2011; Konarski et al., 2008). Abnormalities in neuronal apoptosis have 
been hypothesized to contribute to the brain structural changes that occur in mood 
disorders (Szuster-Ciesielska et al., 2008). Minocycline has been shown to have anti-
apoptotic and anti-oxidative properties within the central nervous system (Soczynska et 
al., 2012). Studies show that minocycline is anti-apoptotic through three main 
mechanisms: 1) by reducing the release of apoptotic agents from mitochondria 2) 
enhancing the release of anti-apoptotic factors 3) by reducing oxidative stress (Noble et. 
al, 2009). Minocycline exerts antioxidant properties by suppressing free radical 
generation and by directly scavenging free radicals (Kraus et al., 2005). This reduces 
oxidative stress, which been hypothesized to play a role in the pathophysiology of 
bipolar disorder and depression. In both disorders, increased levels of free radicals 
have been reported (Andreazza et al., 2008; Dhir & Kulkarni, 2011; Suzuki et al., 2001). 
 
Another important mediator of neuroplasticity in mood disorders is the excitatory 
neurotransmitter glutamate. Abnormal levels of glutamate have been found in the 
plasma, cerebrospinal fluid and brain tissue of patients suffering from mood disorders 
(Sanacora et al., 2012). In depressed patients decreased levels of glutamate metabolites 
have been observed, whereas in bipolar patients these are increased (Yuksel & Ongur, 
2010). In bipolar patients, glutamate levels may be dependent on the mood episode 
with studies showing that the glutamine/glutamate ratio is reduced in the depressive 
phase of illness but increased during manic episodes (Sanacora et al., 2012). These 
glutamatergic abnormalities may be associated with neuroinflammatory processes in a 
sub-group of mood disorder patients. It has been proposed that disturbances to the 
kynurenine pathway may lead to glutamatergic disturbances in some patients with 
mood disorders rather than due to a direct impact on glutamate transporters or 
receptors (Steiner et al., 2012). The increased QUIN/KYNA ratio may lead to excitoxicity 
causing astrocyte loss. Astrocytes are the main cells responsible for glutamate reuptake 








synaptic activation leading to neurotoxicity, production of free radicals and apoptosis 
(Choudary et al., 2005; Muller & Schwarz, 2007; Myint 2012).  Minocycline has been 
shown to indirectly modulate glutamate transmission in several animal studies 
(Baptiste et al., 2004; Nie et al., 2010, Song et al., 2006). This effect may be due to 
minocycline’s anti-inflammatory and anti-oxidative properties, which result in reduced 
production of QUIN in the kynuerenine pathway (cf. Figure 4) (Myint 2012).  
 
The evidence summarized above would indicate that inflammation is associated with 
multiple interacting pathways including apoptotic, neurotrophic, oxidative, and 
glutamatergic pathways, which may be involved in the pathophysiology of mood 
disorders. However, a wider search in this area shows that the evidence remains 
conflicting and that it is most likely that the pathophysiology of mood disorders is 
highly heterogeneous, which makes treatment trials for these conditions especially 
challenging. Current evidence shows that minocycline may exert effects on several of 
the interacting systems that may be implicated in the pathophysiology of mood 
disorders. The pilot trial of minocycline as an add-on treatment for patients with 
treatment-resistant depression provides vital proof-of-concept evidence that it may 
have therapeutic potential in these common and often disabling conditions. I hope that 
our findings will inform the development of more rigorous, larger scale efficacy studies 
that will include robust mechanistic components such as measurement of inflammatory 
biomarkers and/or neuroimaging. The results of these studies will determine whether 
















Chapter 7: Conclusion 
 
7.1 Implications for future research 
The findings from the research conducted during my MD (Res.) show that current 
evidence for the use of anti-inflammatories as treatments for mood disorders remains 
inconsistent. Current studies are limited by small sample sizes, short durations, 
differing baseline symptomatology and poorly defined illness durations, which makes it 
impossible to provide recommendations on the routine clinical use of these agents in 
the treatment of bipolar disorder and MDD. The most investigated anti-inflammatory 
treatment thus far is celecoxib, with many studies reporting antidepressant effects 
when used as an adjunct or as monotherapy (Müller et al., 2006, Akhondzadeh et al., 
2009, Abbasi et al., 2012, Jafari et al., 2015, Majid et al., 2015). There are also indications 
that celecoxib may have antimanic properties, although this assumption is based on a 
small study not evaluating long-term effects on response and remission (Arabzadeh et 
al., 2015). Although it has been reported that non-steroidal anti-inflammatory drugs 
carry an increased risk for gastrointestinal (Wolfe et al., 1999) and cardiovascular 
(Mukherjee et al., 2001) adverse effects, this has not been supported by my analysis. 
However, it is important to note that some studies did not provide any comment on 
adverse effects (Berk et al., 2012, Kargar et al., 2015, Magalhães et al., 2013). 
Furthermore, given the short study period for many of the trials conducted thus far, it is 
possible that adverse effects were not identified in the study timeframe. Given these 
important caveats, it is imperative to proceed cautiously before implementing celecoxib 
or other anti-inflammatory treatments in routine clinical practice, and the potential 
therapeutic benefits in mood disorder must be balanced against the risk of adverse 
effects.  
 
Given the small number of studies that have investigated cytokine inhibitors, N-
acetylcysteine and minocycline for the treatment of mood disorders, further high 
quality controlled clinical trials are needed to contribute to the current body of 








potential role as an augmentation strategy in patients with treatment-resistant 
depression, this was only a pilot trial with a small sample size and more studies are 
required. The objective of our pilot study was to inform the study design in terms of 
recruitment, randomization, intervention implementation, biomarker collection, 
blinded assessment procedures and retention, for a larger scale hypothesis testing 
study. We achieved these aims, whilst also showing that minocycline may be a safe and 
effective treatment option for those with persistent depressive symptoms. Of note we 
found a very strong clinical effect, which was generally supported by secondary 
outcome measures. Future studies with larger sample sizes and longer follow-up 
periods, incorporating robust mechanistic components are required to confirm our 
findings and to determine the mode of potential antidepressant action of minocycline. 
Similarly, more large-scale clinical trials of celecoxib and other anti-inflammatories for 
patients with depression (both unipolar and bipolar) and mania are warranted. Such 
trials will assess longer-term safety and tolerability as well as effects on response and 
remission rates in both major depressive disorder and bipolar disorder. 
 
I suggest that future treatment trials should also include the measurement of 
biomarkers to identify whether the clinical benefits of anti-inflammatory medications 
occur alongside a change in inflammatory activity, or in only a biological sub-group of 
patients experiencing a mood disorder. Studies have already found that patients with 
both depression and bipolar disorder may have abnormal levels of circulating 
inflammatory markers (Goldstein et al., 2009, Howren et al., 2009, Dowlati et al., 2010).  
A recent meta-analysis has found that in MDD, these levels may normalize with 
treatment and the authors identified TNF-α as a potential marker for treatment-
resistant depression (Strawbridge et al., 2015). However, plasma cytokines are strongly 
affected by environmental factors (e.g. age, gender, exercise, obesity, insulin resistance, 
smoking), and by the heterogeneity of mood disorder itself, and so exhibit high inter-
individual variance. Instead it has been suggested that measuring the pro-inflammatory 
state of monocytes, the main cytokine producers, via gene expression may be a more 








RCTs of anti-inflammatory medications should attempt to incorporate these putative 
biomarkers to determine whether the mechanism of any antidepressant or antimanic 
action is due to the inhibition of inflammatory processes. The results of such studies 
may provide clinicians with clear guidelines on when to implement anti-inflammatory 
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